Scarica l'app Stockscreener
22.52
0.49%
-0.11
Dopo l'orario di chiusura:
22.52
Precedente Chiudi:
$22.63
Aprire:
$22.83
Volume 24 ore:
2.54M
Relative Volume:
0.47
Capitalizzazione di mercato:
$11.19B
Reddito:
$4.45B
Utile/perdita netta:
$205.00M
Rapporto P/E:
56.30
EPS:
0.4
Flusso di cassa netto:
$372.00M
1 W Prestazione:
-0.35%
1M Prestazione:
+0.13%
6M Prestazione:
+52.99%
1 anno Prestazione:
+86.89%
Intervallo 1D:
$22.00
$22.96
Intervallo di 1 settimana:
$22.00
$23.06
Portata 52W:
$8.02
$23.70
Elanco Animal Health Inc Stock (ELAN) Company Profile
Nome
Elanco Animal Health Inc
Settore
Telefono
877-352-6261
Indirizzo
450 ELANCO CIRCLE, INDIANAPOLIS
Confronta ELAN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
22.52 | 11.24B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
125.90 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.02 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.95 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
496.72 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-11-21 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2025-11-19 | Aggiornamento | Argus | Hold → Buy |
| 2025-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-07-17 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-06-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-12-09 | Iniziato | UBS | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Market Perform |
| 2024-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | Aggiornamento | Stifel | Hold → Buy |
| 2023-12-19 | Iniziato | Jefferies | Buy |
| 2023-12-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | Iniziato | Exane BNP Paribas | Outperform |
| 2023-04-20 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-08-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-21 | Downgrade | Goldman | Buy → Sell |
| 2022-07-12 | Iniziato | Piper Sandler | Neutral |
| 2021-11-18 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-28 | Downgrade | Stifel | Buy → Hold |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-06-15 | Aggiornamento | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2021-05-11 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2021-04-15 | Iniziato | Stifel | Buy |
| 2021-03-22 | Downgrade | Gabelli & Co | Buy → Hold |
| 2021-02-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | Downgrade | Argus | Buy → Hold |
| 2020-11-09 | Downgrade | Barclays | Overweight → Underweight |
| 2020-08-20 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | Ripresa | Credit Suisse | Neutral |
| 2020-08-04 | Ripresa | Goldman | Buy |
| 2020-07-27 | Downgrade | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | Iniziato | Barclays | Overweight |
| 2019-08-26 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-23 | Iniziato | Guggenheim | Neutral |
| 2019-03-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-02-12 | Iniziato | William Blair | Mkt Perform |
| 2019-01-23 | Iniziato | UBS | Sell |
| 2019-01-15 | Iniziato | Argus | Buy |
| 2018-10-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Elanco Animal Health Inc Borsa (ELAN) Ultime notizie
ELAN SEC FilingsElanco Animal Health 10-K, 10-Q, 8-K Forms - Stock Titan
Elanco (ELAN) Gains USDA Approval for Befrena Injections - GuruFocus
Elanco (ELAN) Gains USDA Approval for New Canine Dermatology Tre - GuruFocus
Elanco gains approval of Befrena for canine dermatitis - Seeking Alpha
Elanco receives USDA approval for canine dermatitis treatment By Investing.com - Investing.com Canada
Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis - PR Newswire
Voya Investment Management LLC Sells 2,335,093 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco (ELAN) CEO Jeffrey Simmons reports new deferred stock units - Stock Titan
Elanco (ELAN) EVP reports new deferred stock units award - Stock Titan
Targets Report: Will Elanco Animal Health Incorporated 5EA stock outperform value peers2025 EndofYear Setup & Free Low Drawdown Momentum Trade Ideas - moha.gov.vn
Yousif Capital Management LLC Boosts Stock Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
EBITDA per share of Elanco Animal Health, Inc. – FWB:5EA - TradingView — Track All Markets
Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Elanco Animal Health Incorporated $ELAN Shares Sold by Harbor Capital Advisors Inc. - MarketBeat
Exchange Traded Concepts LLC Acquires Shares of 262,281 Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Earnings Notes - Trefis
Elanco Animal Health Inc (ELAN) director gifts 60,000 shares - Stock Titan
Elanco Animal Health working to combat New World screwwrorm - norfolkneradio.com
Oasis of Zen - Exhibitor Online
Middle East And Africa Animal Healthcare Market Forecast - openPR.com
Jim Cramer on Elanco Animal Health: "They Are Doing Everything Right" - Finviz
How Conditional FDA Approval of Credelio Quattro-CA1 Could Impact Elanco Animal Health (ELAN) Investors - Yahoo Finance
Jim Cramer on Elanco Animal Health: “They Are Doing Everything Right” - Yahoo Finance
Douglas Lane & Associates LLC Cuts Stake in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health (FRA:5EA) EV-to-OCF : 22.34 (As of Dec. 21, 2025) - GuruFocus
Does Elanco’s 85% 2025 Rally Match Its Long Term Valuation Prospects? - Yahoo Finance
Veterinary Medicine Market Size to Hit USD 98.51 Billion by 2033, Growing at a CAGR of 8.11%SNS Insider - GlobeNewswire
Wall Street Zen Downgrades Elanco Animal Health (NYSE:ELAN) to Buy - MarketBeat
Is Elanco Animal Health Incorporated stock dividend yield sustainableJuly 2025 Levels & Risk Controlled Swing Alerts - ulpravda.ru
Is Elanco Animal Health Incorporated stock a contrarian opportunityTrade Ideas & Weekly High Potential Stock Alerts - Улправда
Stifel maintains Buy rating on Elanco Animal Health stock with $27 price target - Investing.com Canada
Will Elanco Animal Health Incorporated stock benefit from automationEarnings Summary Report & AI Enhanced Trading Signals - Bölüm Sonu Canavarı
Elanco CEO Bites Off More Shares of Fast-Rising Stock - Barron's
Is Elanco Animal Health Incorporated (5EA) stock positioned for digital growth eraTrade Risk Assessment & Target Return Focused Picks - DonanımHaber
Companion Animal Vaccine Market is Going to Boom: New Report - openPR.com
Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Steve Cohen, Citadel Investment Group, Elliott Management, Altai Capital, Elanco Animal Health Inc (ELAN), NVIDIA Corp (NVDA), and More - Insider Monkey
Elanco focused on production animals - norfolkneradio.com
Elanco Animal Health (NYSE:ELAN) Price Target Raised to $22.00 - MarketBeat
FDA conditionally approves Elanco’s treatment for screwworm in dogs By Investing.com - Investing.com Australia
FDA conditionally approves Elanco’s treatment for screwworm in dogs - Investing.com India
Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs - PR Newswire
Jim Cramer Praises Elanco Animal Health: 'They've Turned That Company Around' - Benzinga
Elanco Animal Health (ELAN) Receives a Buy from Barclays - The Globe and Mail
Elanco (ELAN): Valuation Check After Insider Buying Spree and New Restructuring Plan - Yahoo Finance
Elanco (ELAN) Stock Is Up, What You Need To Know - The Globe and Mail
Elanco Animal Health Director Purchases 10,000 Shares - TradingView — Track All Markets
[Form 4] Elanco Animal Health Inc Insider Trading Activity - Stock Titan
Elanco Animal Health Inc (ELAN) EVP reports 66.4453 deferred stock units - Stock Titan
Elanco Animal Health Inc. (ELAN) CEO reports new deferred stock units award - Stock Titan
Elanco Animal Health (NYSE:ELAN) Shares Little Changed After Results - Kalkine Media
Elanco Animal Health Inc Azioni (ELAN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.28%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):